BECLOMETHASONE DIPROPIONATE
Clinical safety rating: safe
Animal studies have demonstrated safety
Beclomethasone dipropionate is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through binding to glucocorticoid receptors, leading to inhibition of phospholipase A2, reduced prostaglandin and leukotriene synthesis, and suppression of inflammatory cytokines.
| Metabolism | Beclomethasone dipropionate is metabolized primarily via esterase cleavage to the active metabolite beclomethasone-17-monopropionate, which is further metabolized to beclomethasone and inactive glucuronide conjugates. Hepatic CYP3A4 may play a minor role. |
| Excretion | Primarily fecal (via bile) as metabolites, ~60-70%; renal excretion accounts for <10% of unchanged drug. |
| Half-life | Terminal elimination half-life is 2.8-3.1 hours after inhalation, with a slower phase attributed to slow dissolution from lung tissue; clinical context: supports twice-daily dosing. |
| Protein binding | 87% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | ~20 L/kg after inhalation, indicating extensive tissue distribution; however, clinical significance is limited due to high first-pass metabolism of swallowed portion. |
| Bioavailability | Inhalation: 10-20% of delivered dose reaches systemic circulation (lung absorption); oral: <1% due to first-pass metabolism; intranasal: <1% systemically. |
| Onset of Action | Inhalation: 1-2 weeks for maximal therapeutic effect (asthma control); single dose effect on FEV1 seen within 24 hours; intranasal: 2-7 days for symptom relief. |
| Duration of Action | Inhalation: 12-24 hours after single dose, allows twice-daily dosing; intranasal: 12-24 hours; clinical notes: prolonged use (weeks) required for full anti-inflammatory effect. |
Inhalation: 40-320 mcg twice daily (DPI or pMDI); maximum 640 mcg/day. Intranasal: 1-2 sprays (42-84 mcg) per nostril twice daily. Topical: Apply 0.025% cream/ointment twice daily.
| Dosage form | AEROSOL, METERED |
| Renal impairment | No dosage adjustment required in renal impairment due to minimal renal excretion. |
| Liver impairment | No dosage adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B). For severe impairment (Child-Pugh C), consider monitoring for systemic effects; no specific dose reduction has been established. |
| Pediatric use | Inhalation: 40-80 mcg twice daily (aged 5-11 years), titrated to effect; maximum 320 mcg/day. Intranasal: 1 spray (42 mcg) per nostril twice daily (aged 6-11 years). |
| Geriatric use | No specific dose adjustment required; use lowest effective dose to minimize risk of systemic effects, particularly in patients with comorbid conditions. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Rinse mouth after inhalation to prevent oral candidiasis Adrenal insufficiency may occur when transferring from systemic steroids.
| Breastfeeding | Beclomethasone dipropionate is excreted into breast milk in small amounts. The M/P ratio has not been formally established but is expected to be low (<1) given low systemic bioavailability. Generally considered compatible with breastfeeding; however, use the lowest effective dose and monitor infant for potential adrenal suppression. |
| Teratogenic Risk | Inhaled corticosteroids like beclomethasone dipropionate are generally considered low risk during pregnancy. Systemic absorption is minimal, and studies have not shown a significant increase in major congenital malformations. However, high-dose or prolonged use may be associated with a slight increase in oral clefts (first trimester) and intrauterine growth restriction (third trimester). For intranasal use, risk is negligible. |
■ FDA Black Box Warning
No FDA boxed warning.
| Common Effects | COPD |
| Serious Effects |
["Hypersensitivity to beclomethasone dipropionate or any component of the formulation","Untreated systemic fungal infections","Status asthmaticus (as primary treatment)"]
| Precautions | ["May cause adrenal suppression, especially with high doses or prolonged use","Risk of growth suppression in children","Potential for oropharyngeal candidiasis with inhaled use","Avoid abrupt discontinuation in patients on chronic systemic corticosteroids","Monitor for signs of Cushing's syndrome","Risk of osteoporosis with long-term use","Hypersensitivity reactions including anaphylaxis"] |
| Food/Dietary | No significant food interactions. Avoid grapefruit juice if there is concomitant use of CYP3A4-metabolized drugs (though beclomethasone is primarily hydrolyzed by esterases). No dietary restrictions specific to beclomethasone. |
Loading safety data…
| Fetal Monitoring | For pregnant women: Monitor fetal growth via ultrasound if prolonged high-dose therapy. Assess maternal blood glucose and adrenal function if systemic effects suspected. For neonates: Observe for transient adrenal suppression if mother used high-dose corticosteroids near term. |
| Fertility Effects | Systemic corticosteroids may impair fertility by altering hormone levels, but inhaled beclomethasone at recommended doses is unlikely to affect fertility. No specific human studies on fertility are available. |
| Clinical Pearls | Beclomethasone dipropionate is a prodrug converted to active beclomethasone-17-monopropionate (B17MP). When inhaled, use spacer device to reduce oropharyngeal deposition and risk of oral candidiasis. Rinse mouth after use. Not for acute bronchospasm; rescue inhaler needed. Inhaled corticosteroids may suppress HPA axis at high doses; monitor growth in children. |
| Patient Advice | Use consistently as prescribed; do not stop suddenly. · Rinse mouth with water after each use to prevent thrush. · Do not use for sudden asthma attacks; have rescue inhaler ready. · Prime inhaler before first use or if not used for more than 7 days. · Store at room temperature away from moisture and heat. · Report worsening symptoms, oral thrush, or vision changes. |